Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: jack w garnes jr. who wrote (7117)	4/15/1998 10:55:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

To all "true longs", I would like to call it to your attention that there are a good number of vivus shorters on this thread who either out right bash Vivus or pretend to be long and make constant negative comments. Other threads such as Yahoo are even worse. Vivus is getting waxed for several reasons, 1)Fear that Viagra will be a cure all for ED. 2)Several short funds preying on this fear. 3)Uneducated longs selling their shares based on price drop. 4)Some of the large institutions are shorting their own shares. Some institutions are really pissed at Vivus for not giving them the inside scoop when production problems were noted. December 9ths announcement caught even the big boys with their pants down. By pulling the price down to ridiculous levels they are telling vivus that they are not pleased about not getting vital inside info. BEFORE the general public. Remember these guys eventually want to make money on there long positions up in the 20-40 range. I now understand that word on the street is that Viagra works but not as well as it was hyped. If Viagra was so great Pfizers shares would not be going down. Some will say that the shares were already over- valuated. The shares were so high because of very high expectations for Viagra. The word out now is that Viagra will sell but not at the levels initially expected. Let Pfizer spend their money on advertising. Vivus will benefit in the long run because it is the doctors and not the shorts who in the final analysis will be writing the scripts. The basic fundamentals have not changed.